Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia

Science Translational Medicine

Volumn 6, Issue 236, 2014, Pages

  Perova, Tatiana ^a,b   Grandal, Ildiko ^a   Nutter, Lauryl M J ^a   Papp, Eniko ^a,b   Matei, Irina R ^a,b   Beyene, Joseph ^c   Kowalski, Paul E ^a   Hitzler, Johann K ^a   Minden, Mark D ^b,d   Guidos, Cynthia J ^a,b   Danska, Jayne S ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 61 3606; FOSTAMATINIB; PRE B CELL RECEPTOR; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; UNCLASSIFIED DRUG; 2-(7-(3,4-DIMETHOXYPHENYL)IMIDAZO(1,2-C)PYRIMIDIN-5-YLAMINO)NICOTINAMIDE; NICOTINAMIDE; OXAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER GENETICS; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY; LEUKEMIA CELL; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; XENOTRANSPLANTATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CHEMISTRY; CYTOLOGY; DNA MICROARRAY; ENZYMOLOGY; LEUKEMIA; METABOLISM; MUTATION; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; PRE B LYMPHOCYTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; SCID MOUSE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CHILD; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; MALE; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; NIACINAMIDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXAZINES; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; RECURRENCE; SIGNAL TRANSDUCTION; SPLEEN; TREATMENT OUTCOME;

EID: 84901193055     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008661     Document Type: Article

References (60)

1. C. H. Pui, L. L. Robison, A. T. Look, Acute lymphoblastic leukaemia. Lancet 371, 1030-1043 (2008).
2. C. H. Pui, C. Cheng, W. Leung, S. N. Rai, G. K. Rivera, J. T. Sandlund, R. C. Ribeiro, M. V. Relling, L. E. Kun, W. E. Evans, M. M. Hudson, Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N. Engl. J. Med. 349, 640-649 (2003).
3. F. Locatelli, M. Schrappe, M. E. Bernardo, S. Rutella, How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120, 2807-2816 (2012).
4. E. Liew, E. G. Atenafu, A. D. Schimmer, K. W. Yee, A. C. Schuh, M. D. Minden, V. Gupta, J. M. Brandwein, Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leuk. Res. 36, 1517-1520 (2012).
5. C. H. Pui, W. E. Evans, Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178 (2006).
6. M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, C. L. Willman, N. Winick, B. M. Camitta; Children's Oncology Group, Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 111, 5477-5485 (2008).
7. K. R. Schultz, D. J. Pullen, H. N. Sather, J. J. Shuster, M. Devidas, M. J. Borowitz, A. J. Carroll, N. A. Heerema, J. E. Rubnitz, M. L. Loh, E. A. Raetz, N. J. Winick, S. P. Hunger, W. L. Carroll, P. S. Gaynon, B. M. Camitta, Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109, 926-935 (2007).
8. C. Domenech, M. Mercier, E. Plouvier, M. Puraveau, P. Bordigoni, G. Michel, Y. Benoit, G. Leverger, A. Baruchel, Y. Bertrand, First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: Results of the Cooprall-97 study. Eur. J. Cancer 44, 2461-2469 (2008).
9. D. S. Krause, R. A. Van Etten, Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005).
10. B. J. Druker, C. L. Sawyers, H. Kantarjian, D. J. Resta, S. F. Reese, J. M. Ford, R. Capdeville, M. Talpaz, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
11. K. G. Roberts, R. D. Morin, J. Zhang, M. Hirst, Y. Zhao, X. Su, S. C. Chen, D. Payne-Turner, M. L. Churchman, R. C. Harvey, X. Chen, C. Kasap, C. Yan, J. Becksfort, R. P. Finney, D. T. Teachey, S. L. Maude, K. Tse, R. Moore, S. Jones, K. Mungall, I. Birol, M. N. Edmonson, Y. Hu, K. E. Buetow, I.M. Chen, W. L. Carroll, L. Wei, J. Ma, M. Kleppe, R. L. Levine,G. Garcia-Manero, E. Larsen, N. P. Shah, M. Devidas, G. Reaman, M. Smith, S. W. Paugh, W. E. Evans, S. A. Grupp, S. Jeha, C. H. Pui, D. S. Gerhard, J. R. Downing, C. L. Willman, M. Loh, S. P. Hunger, M. A. Marra, C. G. Mullighan, Genetic alterations activating kinase and cytokine receptor signaling in highrisk acute lymphoblastic leukemia. Cancer Cell 22, 153-166 (2012).
12. S. K. Tasian, M. Y. Doral, M. J. Borowitz, B. L. Wood, I. M. Chen, R. C. Harvey, J . M. Gastier-Foster, C. L. Willman, S. P. Hunger, C. G. Mullighan, M. L. Loh, Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 120, 833-842 (2012).
13. S. L. Maude, S. K. Tasian, T. Vincent, J.W. Hall, C. Sheen, K. G. Roberts, A. E. Seif, D. M. Barrett, I.M. Chen, J. R. Collins, C. G. Mullighan, S. P. Hunger, R. C. Harvey, C. L. Willman, J. S. Fridman, M. L. Loh, S. A. Grupp, D. T. Teachey, Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120, 3510-3518 (2012).
14. S. Herzog, M. Reth, H. Jumaa, Regulation of B-cell proliferation and differentiation by pre-Bcell receptor signalling. Nat. Rev. Immunol. 9, 195-205 (2009).
15. I. R. Matei, C. J. Guidos, J. S. Danska, ATM-dependent DNA damage surveillance in T-cell development and leukemogenesis: The DSB connection. Immunol. Rev. 209, 142-158 (2006).
16. C. J. Guidos, C. J. Williams, I. Grandal, G. Knowles, M. T. Huang, J. S. Danska, V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 10, 2038-2054 (1996).
17. M. Nacht, A. Strasser, Y. R. Chan, A. W. Harris, M. Schlissel, R. T. Bronson, T. Jacks, Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev. 10, 2055-2066 (1996).
18. C. H. Pui, M. V. Relling, D. Campana, W. E. Evans, Childhood acute lymphoblastic leukemia. Rev. Clin. Exp. Hematol. 6, 161-180 (2002).
19. S. Braselmann, V. Taylor, H. Zhao, S. Wang, C. Sylvain, M. Baluom, K. Qu, E. Herlaar, A. Lau, C. Young, B. R. Wong, S. Lovell, T. Sun, G. Park, A. Argade, S. Jurcevic, P. Pine, R. Singh, E. B. Grossbard, D. G. Payan, E. S. Masuda, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319, 998-1008 (2006).
20. R. A. Gladdy, M. D. Taylor, C. J. Williams, I. Grandal, J. Karaskova, J. A. Squire, J. T. Rutka, C. J. Guidos, J. S. Danska, The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficientmice. Cancer Cell 3, 37-50 (2003).
21. R. R. Hardy, K. Hayakawa, B cell development pathways, Annu. Rev. Immunol. 19, 595-621 (2001).
22. A. Mócsai, J. Ruland, V. L. Tybulewicz, The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387-402 (2010).
23. M. T. Furlong, A. M. Mahrenholz, K. H. Kim, C. L. Ashendel, M. L. Harrison, R. L. Geahlen, Identification of the major sites of autophosphorylation of the murine protein-tyrosine kinase Syk. Biochim. Biophys. Acta 1355, 177-190 (1997).
24. P. O. Krutzik, J. M. Irish, G. P. Nolan, O. D. Perez, Analysis of protein phosphorylation and cellular signaling events by flow cytometry: Techniques and clinical applications. Clin. Immunol. 110, 206-221 (2004).
25. D. G. Efremov, L. Laurenti, The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin. Investig. Drugs 20, 623-636 (2011).
26. H. Jumaa, L. Bossaller, K. Portugal, B. Storch, M. Lotz, A. Flemming, M. Schrappe, V. Postila, P. Riikonen, J. Pelkonen, C. M. Niemeyer, M. Reth, Deficiency of the adaptor SLP-65 in pre- B-cell acute lymphoblastic leukaemia. Nature 423, 452-456 (2003).
27. D. Trageser, I. Iacobucci, R. Nahar, C. Duy, G. von Levetzow, L. Klemm, E. Park, W. Schuh, T. Gruber, S. Herzog, Y. M. Kim, W. K. Hofmann, A. Li, C. T. Storlazzi, H. M. Jäck, J. Groffen, G. Martinelli, N. Heisterkamp, H. Jumaa, M. Müschen, Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J. Exp. Med. 206, 1739-1753 (2009).
28. J. W. Friedberg, J. Sharman, J. Sweetenham, P. B. Johnston, J. M. Vose, A. Lacasce, J. Schaefer-Cutillo, S. De Vos, R. Sinha, J. P. Leonard, L. D. Cripe, S. A. Gregory, M. P. Sterba, A. M. Lowe, R. Levy, M. A. Shipp, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578-2585 (2010).
29. S. A. Armstrong, M. E. Mabon, L. B. Silverman, A. Li, J. G. Gribben, E. A. Fox, S. E. Sallan, S. J. Korsmeyer, FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103, 3544-3546 (2004).
30. V. T. Bicocca, B. H. Chang, B. K. Masouleh, M. Muschen, M. M. Loriaux, B. J. Druker, J. W. Tyner, Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 22, 656-667 (2012).
31. N. Yamamoto, K. Takeshita, M. Shichijo, T. Kokubo, M. Sato, K. Nakashima, M. Ishimori, H. Nagai, Y. F. Li, T. Yura, K. B. Bacon, The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c] pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J. Pharmacol. Exp. Ther. 306, 1174-1181 (2003).
32. A. Gazit, K. Yee, A. Uecker, F. D. Böhmer, T. Sjöblom, A. Ostman, J. Waltenberger, G. Golomb, S. Banai, M. C. Heinrich, A. Levitzki, Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg. Med. Chem. 11 , 2007-2018 (2003).
33. L. J. Lombardo, F. Y. Lee, P. Chen, D. Norris, J. C. Barrish, K. Behnia, S. Castaneda, L. A. Cornelius, J. Das, A. M. Doweyko, C. Fairchild, J. T. Hunt, I. Inigo, K. Johnston, A. Kamath, D. Kan, H. Klei, P. Marathe, S. Pang, R. Peterson, S. Pitt, G. L. Schieven, R. J. Schmidt, J. Tokarski, M. L.Wen, J. Wityak, R. M. Borzilleri, Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2- hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5- carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661 (2004).
34. A. Agliano, I. Martin-Padura, P. Mancuso, P. Marighetti, C. Rabascio, G. Pruneri, L. D. Shultz, F. Bertolini, Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rg null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int. J. Cancer 123, 2222-2227 (2008).
35. + cells. Blood 106, 1259-1261 (2005).
36. L. H. Meyer, S. M. Eckhoff, M. Queudeville, J. M. Kraus, M. Giordan, J. Stursberg, A. Zangrando, E. Vendramini, A. Möricke, M. Zimmermann, A. Schrauder, G. Lahr, K. Holzmann, M. Schrappe, G. Basso, K. Stahnke, H. A. Kestler, G. Te Kronnie, K. M. Debatin, Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell 19, 206-217 (2011).
37. J. M. Sancho, J. M. Ribera, A. Oriol, J. M. Hernandez-Rivas, C. Rivas, C. Bethencourt, R. Parody, G. Deben, J. L. Bello, E. Feliu; Programa para el Estudio y Tratamiento de Hemopatias Malignas Group, Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: Frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer 106, 2540-2546 (2006).
38. A. Redaelli, B. L. Laskin, J. M. Stephens, M. F. Botteman, C. L. Pashos, A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur. J. Cancer Care 14, 53-62 (2005).
39. M. I. Davis, J. P. Hunt, S. Herrgard, P. Ciceri, L. M. Wodicka, G. Pallares, M. Hocker, D. K. Treiber, P. P. Zarrinkar, Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
40. K. S. Lau, T. Zhang, K. R. Kendall, D. Lauffenburger, N. S. Gray, K. M. Haigis, BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PLOS One 7, e41343 (2012).
41. M. L. Loh, J. Zhang, R. C. Harvey, K. Roberts, D. Payne-Turner, H. Kang, G. Wu, X. Chen, J. Becksfort, M. Edmonson, K. H. Buetow, W. L. Carroll, I. M. Chen, B. Wood, M. J. Borowitz, M. Devidas, D. S. Gerhard, P. Bowman, E. Larsen, N. Winick, E. Raetz, M. Smith, J. R. Downing, C. L. Willman, C. G. Mullighan, S. P. Hunger, Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group TARGET Project. Blood 121, 485-488 (2013).
42. J. Zhang, C. A. Benavente, J. McEvoy, J. Flores-Otero, L. Ding, X. Chen, A. Ulyanov, G. Wu, M. Wilson, J. Wang, R. Brennan, M. Rusch, A. L. Manning, J. Ma, J. Easton, S. Shurtleff, C. Mullighan, S. Pounds, S. Mukatira, P. Gupta, G. Neale, D. Zhao, C. Lu, R. S. Fulton, L. L. Fulton, X. Hong, D. J. Dooling, K. Ochoa, C. Naeve, N. J. Dyson, E. R. Mardis, A. Bahrami, D. Ellison, R. K. Wilson, J. R. Downing, M. A. Dyer, A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481 , 329-334 (2012).
43. M. Dühren-von Minden, R. Übelhart, D. Schneider, T. Wossning, M. P. Bach, M. Buchner, D. Hofmann, E. Surova, M. Follo, F. Köhler, H. Wardemann, K. Zirlik, H. Veelken, H. Jumaa, Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489, 309-312 (2012).
44. R. E. Davis, V. N. Ngo, G. Lenz, P. Tolar, R. M. Young, P. B. Romesser, H. Kohlhammer, L. Lamy, H. Zhao, Y. Yang, W. Xu, A. L. Shaffer, G. Wright, W. Xiao, J. Powell, J. K. Jiang, C. J. Thomas, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, R. D. Gascoyne, J. M. Connors, N. A. Johnson, L. M. Rimsza, E. Campo, E. S. Jaffe, W. H. Wilson, J. Delabie, E. B. Smeland, R. I. Fisher, R. M. Braziel, R. R. Tubbs, J. R. Cook, D. D. Weisenburger, W. C. Chan, S. K. Pierce, L. M. Staudt, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92 (2010).
45. C. K. Hahn, J. E. Berchuck, K. N. Ross, R. M. Kakoza, K. Clauser, A. C. Schinzel, L. Ross, I. Galinsky, T. N. Davis, S. J. Silver, D. E. Root, R. M. Stone, D. J. DeAngelo, M. Carroll, W. C. Hahn, S. A. Carr, T. R. Golub, A. L. Kung, K. Stegmaier, Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16, 281-294 (2009).
46. Cancer Genome atlas Research Network, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
47. E. Schweighoffer, L. Vanes, J. Nys, D. Cantrell, S. McCleary, N. Smithers, V. L. Tybulewicz, The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 38, 475-488 (2013).
48. L. Chen, P. Juszczynski, K. Takeyama, R. C. Aguiar, M. A. Shipp, Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 108, 3428-3433 (2006).
49. P. A. Goodman, C. M. Wood, A. Vassilev, C. Mao, F. M. Uckun, Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene 20, 3969-3978 (2001).
50. I. Iacobucci, N. Iraci, M. Messina, A. Lonetti, S. Chiaretti, E. Valli, A. Ferrari, C. Papayannidis, F. Paoloni, A. Vitale, C. T. Storlazzi, E. Ottaviani, V. Guadagnuolo, S. Durante, M. Vignetti, S. Soverini, F. Pane, R. Foà, M. Baccarani, M. Müschen, G. Perini, G. Martinelli, IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLOS One 7, e40934 (2012).
51. T. Wossning, S. Herzog, F. Köhler, S. Meixlsperger, Y. Kulathu, G. Mittler, A. Abe, U. Fuchs, A. Borkhardt, H. Jumaa, Deregulated Syk inhibits differentiation and induces growth factor - independent proliferation of pre-B cells. J. Exp. Med. 203, 2829-2840 (2006).
52. C. H. Pui, D. Campana, D. Pei, W. P. Bowman, J. T. Sandlund, S. C. Kaste, R. C. Ribeiro, J. E. Rubnitz, S. C. Raimondi, M. Onciu, E. Coustan-Smith, L. E. Kun, S. Jeha, C. Cheng, S. C. Howard, V. Simmons, A. Bayles, M. L. Metzger, J. M. Boyett, W. Leung, R. Handgretinger, J. R. Downing, W. E. Evans, M. V. Relling, Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730-2741 (2009).
53. G. K. Smyth, Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
54. R. C. Gentleman, V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, R. Irizarry, F. Leisch, C. Li, M. Maechler, A. J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney, J. Y. Yang, J. Zhang, Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 5, R80.1-R80.16 (2004).
55. R. A. Irizarry, B. M. Bolstad, F. Collin, L. M. Cope, B. Hobbs, T. P. Speed, Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).
56. R. A. Irizarry, B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, T. P. Speed, Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
57. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300 (1995).
58. J. S. Danska, F. Pflumio, C. J. Williams, O. Huner, J. E. Dick, C. J. Guidos, Rescue of T cell-specific V(D)J recombination in SCID mice by DNA-damaging agents. Science 266, 450-455 (1994).
59. N. Kotecha, P. O. Krutzik, J. M. Irish, Web-based analysis and publication of flow cytometry experiments. Curr. Protoc. Cytom. Chapter 10, Unit10.17 (2010).
60. F. Mazurier, M. Doedens, O. I. Gan, J. E. Dick, Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat. Med. 9, 959-963 (2003).